Stock Analysis, Dividends, Split History

NOG / Northern Oil and Gas, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)403.79
Enterprise Value ($M)1,666.33
Book Value ($M)-147.82
Book Value / Share-0.50
Price / Book-6.98
NCAV ($M)-754.92
NCAV / Share-2.54
Price / NCAV-1.37
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 66,791,633
Common Shares Outstanding 65,944,133
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)0.02
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.75
Income Statement (mra) ($M)
Oil And Gas Sales Revenue223,963,010.00
Other Sales Revenue Net23,314.00
Operating Income60.49
Net Income-9.19
Earnings Per Share Basic-0.15
Earnings Per Share Diluted-0.15
Cash Flow Statement (mra) ($M)
Cash From Operations72.97
Cash from Investing-119.24
Cash from Financing72.97
Identifiers and Descriptors
Central Index Key (CIK)1104485
Related CUSIPS
665531959 665531909

Split History

Stock splits are used by Northern Oil and Gas, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Favorable Demand-Supply Mix to Boost Crude Oil Price: 5 Picks

2018-09-13 zacks
Crude oil prices are expected to remain stable in rest of 2018 as well as in 2019 primarily backed by strong demand and supply shortage. A likely dip in U.S. crude oil production and supply bottlenecks in Iran, Venezuela and Algeria owing to geopolitical issues are major supply side concerns. Meanwhile, the global demand for petroleum remains firm and is anticipated to grow next year. This will enable the crude price to remain robust in both 2018 and 2019. (9-3)

The Zacks Analyst Blog Highlights: Oasis Midstream, TC PipeLines, Phillips, Chaparral and Northern Oil

2018-09-13 zacks
Chicago, IL –September 13, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oasis Midstream Partners LP (OMP - Free Report) , TC PipeLines, LP (TCP - Free Report) , Phillips 66 (PSX - Free Report) , Chaparral Energy, Inc. (11-1)

ReneSola (SOL) to Develop 13.3MW Community Solar Portfolio

2018-09-12 zacks
ReneSola Ltd (SOL - Free Report) plans to develop 13.3 Megawatt (MW) community solar portfolio, which will be acquired by Nautilus Solar Energy, LLC. This will be the company’s second solar project to be acquired by Nautilus Solar. This community solar portfolio also qualified under Xcel Energy's (XEL - Free Report) rapidly expanding community solar program in Minnesota and will supply clean energy to the customers. (8-0)

Hurricane Florence, Iran Fears Boost Oil Prices: 5 Picks

2018-09-12 zacks
The U.S. East Coast, particularly the Carolinas, is bracing itself for what could be the worst hurricane in nearly three decades. Hurricane Florence, a Category 4 storm, is likely to make landfall by early Friday. With smaller storms like Tropical Storm Isaac likely to follow in its wake, fuel demand is experiencing an increase. These storms could also disrupt production and refining activities significantly. (8-0)

Louisiana & Wyoming Now Richer by a Number of Onshore Rigs

2018-09-10 zacks
In its weekly release, Baker Hughes (BHGE - Free Report) — a GE company — reported in-line U.S. rig count. (12-0)

CUSIP: 665531109